Format

Send to:

Choose Destination
See comment in PubMed Commons below
Antimicrob Agents Chemother. 2014 Jun;58(6):3533-7. doi: 10.1128/AAC.02340-14. Epub 2014 Mar 31.

Altered pharmacokinetics of piperacillin in febrile neutropenic patients with hematological malignancy.

Author information

  • 1School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia Therapeutics Research Centre, Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Adelaide, Australia fekade.sime@mymail.unisa.edu.au.
  • 2School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia Therapeutics Research Centre, Basil Hetzel Institute for Translational Health Research, The Queen Elizabeth Hospital, Adelaide, Australia.
  • 3SA Pathology and the University of Adelaide, Adelaide, Australia.
  • 4Department of Haematology/Oncology, The Queen Elizabeth Hospital, Adelaide, Australia.
  • 5Cancer Clinical Trials, The Queen Elizabeth Hospital, Adelaide, Australia.
  • 6Royal Brisbane and Women's Hospital, Herston, Brisbane, Queensland, Australia Burns, Trauma, and Critical Care Research Centre, University of Queensland, Herston, Brisbane, Queensland, Australia.
  • 7Department of Intensive Care Medicine, The Queen Elizabeth Hospital, Adelaide, Australia.
  • 8School of Pharmacy and Medical Sciences, University of South Australia, Adelaide, Australia Royal Brisbane and Women's Hospital, Herston, Brisbane, Queensland, Australia Burns, Trauma, and Critical Care Research Centre, University of Queensland, Herston, Brisbane, Queensland, Australia.

Abstract

This study assessed the pharmacokinetics and dosing adequacy of piperacillin in febrile neutropenic patients after the first dose. Pharmacokinetic analysis was performed using noncompartmental methods. We observed an elevated volume of distribution (29.7 ± 8.0 liters [mean ± standard deviation]) and clearance (20.2 ± 7.5 liters/h) compared to data from other patient populations. Antibiotic exposure did not consistently result in therapeutic targets. We conclude that alternative dosing strategies guided by therapeutic drug monitoring may be required to optimize exposure.

Copyright © 2014, American Society for Microbiology. All Rights Reserved.

PMID:
24687508
[PubMed - in process]
PMCID:
PMC4068433
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire Icon for PubMed Central
    Loading ...
    Write to the Help Desk